SCHEMBL4177686

SCHEMBL4177686

O=C(c1csc(NS(=O)(=O)c2ccccc2)n1)N1CCCC1c1ccccc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.51
TRPC3 Q13507 4/20 0.48
TRPC6 Q9Y210 4/20 0.48
HSP90AA1 P07900 3/20 0.46
HSP90AB1 P08238 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 2/20 0.44
NPC1 O15118 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
RAB9A P51151 1/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM1A O60341 4/20 0.42
TRPA1 O75762 1/20 0.40
CACNA1C Q13936 1/20 0.40
SCN5A Q14524 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
TRPV4 Q9HBA0 1/20 0.40
ADAM17 P78536 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4179996 0.89 SCN9A (0.51) SCN9ATRPC3TRPC6SMN1; SMN2ALDH1A1
SCHEMBL4172599 0.88 TRPC3 (0.61) SCN9ATRPC3TRPC6TRPA1CACNA1C
SCHEMBL3163236 0.87 KDM1A (0.41) SCN9ATRPC3TRPC6SMN1; SMN2ALDH1A1
SCHEMBL4176165 0.86 SCN9A (0.49) SCN9ATRPC3TRPC6HSP90AA1HSP90AB1
SCHEMBL4165105 0.85 TRPC3 (0.66) SCN9ATRPC3TRPC6SMN1; SMN2ALDH1A1
SCHEMBL4177448 0.84 TRPC3 (0.54) SCN9ATRPC3TRPC6HSP90AA1HSP90AB1
SCHEMBL4170692 0.84 TRPC3 (0.65) SCN9ATRPC3TRPC6SMN1; SMN2ALDH1A1
SCHEMBL4180201 0.83 SCN9A (0.49) SCN9ATRPC3TRPC6SMN1; SMN2NPC1
SCHEMBL4176159 0.81 TRPC3 (0.61) SCN9ATRPC3TRPC6ALDH1A1KDM1A
SCHEMBL4181512 0.81 TRPC3 (0.71) SCN9ATRPC3TRPC6ALDH1A1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN9A 51/4885TRPC3 57/4885TRPC6 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.